Navigation Links
Alexza Reports 2012 Fourth Quarter and Full Year Financial Results
Date:3/26/2013

uctive pulmonary disease (COPD), or other lung disease associated with bronchospasm
  • Acute respiratory signs / symptoms (e.g., wheezing)
  • Current use of medications to treat airways disease, such as asthma or COPD
  • History of bronchospasm following ADASUVE treatment
  • Known hypersensitivity to loxapine and amoxapine
  • WARNINGS AND PRECAUTIONS:

  • Neuroleptic Malignant Syndrome: May develop in patients treated with antipsychotic drugs. Discontinue treatment
  • Hypotension and Syncope: Use with caution in patients with known cardiovascular or cerebrovascular disease
  • Seizure: Use with caution in patients with a history of seizures or with conditions that lower the seizure threshold
  • Potential for Cognitive and Motor Impairment: Use caution when driving or operating machinery
  • Cerebrovascular Adverse Reactions: Increased incidence of stroke and transient ischemic attack in elderly patients with dementia-related psychosis treated with antipsychotic drugs
  • ADVERSE REACTIONS: The most common adverse reactions (incidence ≥ 2% and greater than placebo) in clinical studies in patients with agitation treated with ADASUVE were dysgeusia, sedation, throat irritation.Safe Harbor Statement

    Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document. Clinical and corporate milestones guidance is as of March 26, 2013 and financial guidance relating to the Company's current cash, cash equivalents, investments and restricted cash is based upon balances as of December 31, 2012 and certain subsequent events.

    This news release and the planned conferen
    '/>"/>

    SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
    2. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
    3. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
    4. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
    5. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
    6. Alexza Announces Management Promotions
    7. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
    8. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
    9. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
    10. Alexza Receives Complete Response Letter for Adasuve™ NDA
    11. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
    (Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
    (Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
    Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
    (Date:5/5/2015)... Seattle, WA (PRWEB) May 05, 2015 Dealing ... be a strenuous and complicated task. Personal injury lawyers are ... lawyers are created equal. In their latest article , ... individuals should search for when choosing a personal injury lawyer ... a personal injury case is a waste of time if ...
    (Date:5/5/2015)... 05, 2015 The report ... provides comparative analysis on the therapeutic development ... pipelines by identifying new targets and MOAs ... report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html ... Fibrosis – Pipeline Review, H2 2014 report ...
    (Date:5/5/2015)... Texting has become a common and integral part ... text as a way to communicate with patients and other ... so to assure medical records are updated after patient interaction. ... When providers transmit protected health information (PHI), or even have ... of violating the Health Insurance Portability and Accountability Act (HIPAA) ...
    (Date:5/5/2015)... 2015 No one cares about health problems ... Control and Prevention cite multiple sources causing poor indoor ... indoor air quality (pollution) can bother your eyes, nose, and ... problems and cancer.” , Toxic chemicals often get into the ... or water, or in some cases, absorb them through our ...
    (Date:5/4/2015)... Garden City, NY (PRWEB) May 05, 2015 ... honors Patti Hommes as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to recognize Patti with this important honor,” says NAPW ...
    Breaking Medicine News(10 mins):Health News:5 Top Qualifications for Personal Injury Lawyer Disclosed in Latest Article by The Jones Firm 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3Health News:HIPAA Compliant Texting Service from MedXcom now available for Policyholders 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 3Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2
    ... 29 The National Patient,Safety Foundation,s theme this ... the importance of improving healthcare as a joint,effort ... Supporting National Patient Safety Awareness Week, March 2-8, ... ) urges communities to,actively partner with local hospitals ...
    ... Cardiogenesis,Corporation (Pink Sheets: CGCP), a leading developer ... today announced that,it will delay its earnings release ... full year ended December 31, 2007. The earnings ... Tuesday, March 4,2008., The Company noted that ...
    ... the Only Provider to Offer Practice Management and ... of Mental Health Care Providers, GREAT RIVER, ... provider of enterprise-wide software and services for health ... Therapist,Helper product suite and operations from Nightingale VantageMed,Corporation, ...
    ... PRINCETON, N.J., Feb. 29 Orchid Cellmark Inc.,(Nasdaq: ... testing,services, will release its fourth quarter and full year ... 7:00 am EST, and is,hosting a conference call and ... the same day. Management will discuss financial results for ...
    ... heart, liver and lung transplants at UCSF Medical ... according to new data compiled by the Scientific ... Released on January 11, the report measures performance ... facilities in the United States, including waiting list ...
    ... and benefits still outweigh risks, experts say , , FRIDAY, ... the risk for tendon problems, French researchers report. , ... rare, considering the huge number of statin prescriptions," wrote ... March issue of Arthritis Care and Research , ...
    Cached Medicine News:Health News:Encision Supports National Patient Safety Awareness Week 2Health News:Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 3Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 4Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Survival rates exceed national averages for UCSF heart, liver and lung transplant programs 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: